Skip to main content
. 2017 Sep 21;8(60):101520–101534. doi: 10.18632/oncotarget.21148

Figure 1. In vitro effects of AXT050 on liver cancer cells.

Figure 1

(A) AXT050 significantly reduced the adhesion of HuH7, Hep3b and HepG2 HCC cell lines. Data presented as mean ± SEM; HuH7 (p = <0.0001), Hep3b (p = <0.0001), and HepG2 (p = 0.0001) by 1-way ANOVA. *, **, or *** designate p values ≤ 0.05, 0.01, or 0.001 respectively by Tukey test for differences compared to the 0 μM AXT050 samples. (B) AXT050 significantly inhibited the migration of HuH7, Hep3b and HepG2 HCC cell lines. Data presented as mean ± SEM; HuH7 (p = <0.0001), Hep3b (p = <0.0001), and HepG2 (p = <0.0001) by 1-way ANOVA. *, **, or *** designate p values ≤ 0.05, 0.01, or 0.001 respectively by Tukey test for differences compared to the 0 μM AXT050 samples. (C) AXT050 treatment (10 μM, 32 μM, and 100 μM) completely inhibited tube formation by HMEC incubated in HepG2 tumor conditioned media.